Literature DB >> 24424052

Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation.

Huansheng Dong1, Hu Huang, Xinxu Yun, Do-sung Kim, Yinan Yue, Hongju Wu, Alton Sutter, Kenneth D Chavin, Leo E Otterbein, David B Adams, Young-Bum Kim, Hongjun Wang.   

Abstract

Obesity-induced endoplasmic reticulum (ER) stress causes chronic inflammation in adipose tissue and steatosis in the liver, and eventually leads to insulin resistance and type 2 diabetes (T2D). The goal of this study was to understand the mechanisms by which administration of bilirubin, a powerful antioxidant, reduces hyperglycemia and ameliorates obesity in leptin-receptor-deficient (db/db) and diet-induced obese (DIO) mouse models. db/db or DIO mice were injected with bilirubin or vehicle ip. Blood glucose and body weight were measured. Activation of insulin-signaling pathways, expression of inflammatory cytokines, and ER stress markers were measured in skeletal muscle, adipose tissue, and liver of mice. Bilirubin administration significantly reduced hyperglycemia and increased insulin sensitivity in db/db mice. Bilirubin treatment increased protein kinase B (PKB/Akt) phosphorylation in skeletal muscle and suppressed expression of ER stress markers, including the 78-kDa glucose-regulated protein (GRP78), CCAAT/enhancer-binding protein (C/EBP) homologous protein, X box binding protein (XBP-1), and activating transcription factor 4 in db/db mice. In DIO mice, bilirubin treatment significantly reduced body weight and increased insulin sensitivity. Moreover, bilirubin suppressed macrophage infiltration and proinflammatory cytokine expression, including TNF-α, IL-1β, and monocyte chemoattractant protein-1, in adipose tissue. In liver and adipose tissue of DIO mice, bilirubin ameliorated hepatic steatosis and reduced expression of GRP78 and C/EBP homologous protein. These results demonstrate that bilirubin administration improves hyperglycemia and obesity by increasing insulin sensitivity in both genetically engineered and DIO mice models. Bilirubin or bilirubin-increasing drugs might be useful as an insulin sensitizer for the treatment of obesity-induced insulin resistance and type 2 diabetes based on its profound anti-ER stress and antiinflammatory properties.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24424052      PMCID: PMC3929745          DOI: 10.1210/en.2013-1667

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  56 in total

Review 1.  Endoplasmic reticulum stress and type 2 diabetes.

Authors:  Sung Hoon Back; Randal J Kaufman
Journal:  Annu Rev Biochem       Date:  2012-03-23       Impact factor: 23.643

2.  Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes.

Authors:  Umut Ozcan; Erkan Yilmaz; Lale Ozcan; Masato Furuhashi; Eric Vaillancourt; Ross O Smith; Cem Z Görgün; Gökhan S Hotamisligil
Journal:  Science       Date:  2006-08-25       Impact factor: 47.728

3.  Bilirubin can induce tolerance to islet allografts.

Authors:  Hongjun Wang; Soo Sun Lee; Carlotta Dell'Agnello; Vaja Tchipashvili; Joana Costa Pinto d'Avila; Joanna D'Avilla; Eva Czismadia; Beek Yoke Chin; Fritz H Bach
Journal:  Endocrinology       Date:  2005-10-27       Impact factor: 4.736

4.  The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes.

Authors:  Kentaro Ozawa; Mayuki Miyazaki; Munehide Matsuhisa; Katsura Takano; Yoshihisa Nakatani; Masahiro Hatazaki; Takashi Tamatani; Kazuya Yamagata; Jun-Ichiro Miyagawa; Yasuko Kitao; Osamu Hori; Yoshimitsu Yamasaki; Satoshi Ogawa
Journal:  Diabetes       Date:  2005-03       Impact factor: 9.461

5.  Involvement of endoplasmic reticulum stress in insulin resistance and diabetes.

Authors:  Yoshihisa Nakatani; Hideaki Kaneto; Dan Kawamori; Kazutomi Yoshiuchi; Masahiro Hatazaki; Taka-aki Matsuoka; Kentaro Ozawa; Satoshi Ogawa; Masatsugu Hori; Yoshimitsu Yamasaki; Munehide Matsuhisa
Journal:  J Biol Chem       Date:  2004-10-27       Impact factor: 5.157

6.  The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus.

Authors:  Douwe Dekker; Mirrin J Dorresteijn; Margot Pijnenburg; Suzanne Heemskerk; Anja Rasing-Hoogveld; David M Burger; Frank A D T G Wagener; Paul Smits
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-18       Impact factor: 8.311

7.  Donor treatment with carbon monoxide can yield islet allograft survival and tolerance.

Authors:  Hongjun Wang; Soo Sun Lee; Wenda Gao; Eva Czismadia; James McDaid; Robert Ollinger; Miguel P Soares; Kenichiro Yamashita; Fritz H Bach
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

8.  Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with iron status in persons with type 2 diabetes mellitus.

Authors:  Miguel Arredondo; Denisse Jorquera; Elena Carrasco; Cecilia Albala; Eva Hertrampf
Journal:  Am J Clin Nutr       Date:  2007-11       Impact factor: 7.045

9.  Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress.

Authors:  Stanley M H Chan; Ruo-Qiong Sun; Xiao-Yi Zeng; Zi-Heng Choong; Hao Wang; Matthew J Watt; Ji-Ming Ye
Journal:  Diabetes       Date:  2013-01-24       Impact factor: 9.461

Review 10.  Heme oxygenase-1 and carbon monoxide in pulmonary medicine.

Authors:  Dirk-Jan Slebos; Stefan W Ryter; Augustine M K Choi
Journal:  Respir Res       Date:  2003-08-07
View more
  44 in total

Review 1.  Biliverdin reductase isozymes in metabolism.

Authors:  Luke O'Brien; Peter A Hosick; Kezia John; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2015-02-25       Impact factor: 12.015

Review 2.  HO-1 overexpression and underexpression: Clinical implications.

Authors:  George S Drummond; Jeffrey Baum; Menachem Greenberg; David Lewis; Nader G Abraham
Journal:  Arch Biochem Biophys       Date:  2019-08-16       Impact factor: 4.013

Review 3.  Bilirubin in the Liver-Gut Signaling Axis.

Authors:  Abdul-Rizaq Hamoud; Lauren Weaver; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2018-02-03       Impact factor: 12.015

Review 4.  Translational Significance of Heme Oxygenase in Obesity and Metabolic Syndrome.

Authors:  Nader G Abraham; Joshua M Junge; George S Drummond
Journal:  Trends Pharmacol Sci       Date:  2015-10-26       Impact factor: 14.819

5.  Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα.

Authors:  Terry D Hinds; Peter A Hosick; Shujuan Chen; Robert H Tukey; Michael W Hankins; Andrea Nestor-Kalinoski; David E Stec
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-01-17       Impact factor: 4.310

6.  Epoxyeicosatrienoic acids regulate macrophage polarization and prevent LPS-induced cardiac dysfunction.

Authors:  Meiyan Dai; Lujin Wu; Zuowen He; Shasha Zhang; Chen Chen; Xizhen Xu; Peihua Wang; Artiom Gruzdev; Darryl C Zeldin; Dao Wen Wang
Journal:  J Cell Physiol       Date:  2015-09       Impact factor: 6.384

7.  RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.

Authors:  Nicolas Bonnet; Lucie Bourgoin; Emmanuel Biver; Eleni Douni; Serge Ferrari
Journal:  J Clin Invest       Date:  2019-05-23       Impact factor: 14.808

8.  Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?

Authors:  Terry D Hinds; Samuel O Adeosun; Abdulhadi A Alamodi; David E Stec
Journal:  Med Hypotheses       Date:  2016-08-31       Impact factor: 1.538

9.  The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia.

Authors:  Amanda Crider; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-16

Review 10.  Bilirubin, a Cardiometabolic Signaling Molecule.

Authors:  Terry D Hinds; David E Stec
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.